南京招聘

We are establishing an mRNA therapeutics research group in Huiyu Research Institutes of Huiyu Pharmaceutical Company, Chengdu, China. The group will lead and contribute to our mRNA therapeutic platform and pipeline advancement. The group will focus on mRNA therapeutics discovery for cancer immunotherapy. We are seeking a lead mRNA therapeutics scientist, who will bring leadership and broad expertise in mRNA therapeutics discovery for the advancement of cancer immunotherapy.

Job Responsibilities:
1. Lead the mRNA group. Oversee team research activities. Ensure team research progress and cross-site and cross-functional collaborations.
2. Lead and contribute to the development of mRNA therapeutic platform, with the focus on cancer immunotherapy and vaccines.
3. Establish and progress pipeline for mRNA-based cancer therapeutic vaccines. Lead cancer therapeutic vaccine projects. Work closely with cross-functional groups and CROs to progress candidates from discovery to IND-enabling studies.
4. Provide supervision of group members and junior scientists.

Job Requirements:
1. Ph.D. in immunology, vaccine biology, immune-oncology or tumor immunology or related fields. Candidates with >2-5 years of experience in an industry setting are preferred.
2. Experience in team management and project management.
3. Broad experience in vaccine or mRNA therapeutics discovery.
4. Expertise on mRNA cancer vaccine, tumor specific antigen identification, mRNA vaccine designing and functional verification. Deep understanding the molecular mechanisms of antigen presenting and T cell activation.
5. Proven track record of accomplishments in the cancer immunotherapy field.
6. High spirit on innovation, teamwork, and professional dedication. Strong communication skills.

四川汇宇制药股份有限公司 企业介绍

    四川汇宇制药股份有限公司生产基地位于四川省内江经济技术开发区内，占地面积10万平方米,项目总投资10亿元人民币，致力于高端抗肿瘤药物的研发，生产和销售。公司在四川成都双流区“天府国际生物城”设立全球创新药研发中心，将打造抗体抗癌创新药物研发总部及产业化基地，建设包括从事靶向抗肿瘤小分子化学药和大分子生物药研发、中试及产业化的研发中心，占地面积60亩，规划建筑面积88000平方米，可容纳1500名研发人员，计划在2022年建成运行。
    公司以科技创新为导向的发展理念，不断完善小分子化学药物和单克隆抗体生物药物两个技术平台，开发抗肿瘤领域的创新药物，公司一期项目可年产3000万瓶抗癌针剂，实现年产值25亿元人民币。公司的抗癌针剂于2014年通过英国GMP认证，并于同年顺利通过中国GMP认证。2015年7月公司获得欧盟药品放行资质，公司生产的抗癌针剂已经在伊丽莎白女王医院、皇家伦敦医院和剑桥大学附属医院等1200多家欧盟医院作为一线抗癌药物大规模使用。
    公司在美国、英国、法国、澳大利亚、加拿大、中国香港等全球80多个国家和地区建立了销售渠道并启动了当地的药品注册工作，已逐步建立并完善遍布全球的销售网络。同时以致力于改善人类健康为崇高宗旨，以‘关爱生命，追求卓越，简单诚信’为价值导向， 力争把公司打造成一家受人尊敬的国际化制药企业。